Amneal wins FDA approval for generic ocular product TobraDex

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Source:
    Global Banking News (GBN). 07/20/2021.
  • Additional Information
    • Abstract:
      Pharmaceutical company Amneal Pharmaceuticals Inc (NYSE:AMRX) reported on Monday the receipt of the Abbreviated New Drug Application (ANDA) approval from the US Food and Drug Administration (FDA) for generic TobraDex (tobramycin/dexamethasone) in 0.3%/0.1% for treating bacterial ocular infection.